Home » News » Top Five Reads Of The Week

Top Five Reads Of The Week

ConnectSource, from Cardinal Health, is a new cloud-based platform for patients to engage in their care from home. Patients can consult their care manager to ask questions or get reminders about their care. Pharmaceutical companies are also able to access patient care data collected in accordance with HIPPA to optimize treatment. This innovative technology is aimed at streamlining patient care while providing pharmaceutical companies the means to enhance treatment outcomes. (STATNews)

Information technology, widely used in retail marketing, is an untapped information that could be utilized in healthcare. Researchers at Virginia Mason Medical Center in Seattle, WA are working with electronic medical record (EMR) systems to streamline the patient care process. The goal is to cut unnecessary costs accumulated through hospital visits by establishing best practice protocols, computing tools to help physicians make medical decisions and eliminating redundant medical testing by combining these resources into EMR. (hbr.org)

New artificial intelligence technology developments at Zebra Medical Vision could lead to a reduction in missed findings by radiologists. Readings of medical exams are often imperfect due to small discrepancies that the human eye cannot detect as well as human error. Most notably, this AI technology will be able to identify loss in bone density before it leads to fractures, a task that radiologists have not been able to do. The technology is currently being tested at the University of Virginia Health System. (Health Care IT News)

Individuals born with a defect in the RPE65 gene experience blindness but with the advent of Luxturna they could be able to regain some vision. Clinical trials of Luxturna, which could be the first gene therapy for an inherited disease that is approved in the United States, have shown the gene therapy to be successful in 93% of clinical trial participants. Studies are now being conducted to test this gene therapy on a more varied group of participants with RPE65 defects and the long-term results are still undetermined. However, if this new technology is approved by the FDA, it may save many individuals’ vision as well as open new doors to gene therapy as a solution to inherited diseases. (Reuters)

Sleep apnea affects an estimated 22 million Americans each year but the implantable the Remedē System can help these individuals. The Remedē System is a battery-powered system place under the skin in the upper chest. Wires inserted into the patient’ s blood vessels send a signal to the phrenic nerve, which stimulates the diaphragm to restore patients’ breathing. This technology recently received FDA approval and is available to patients as per the counsel of their doctor. (FDA)

Similar posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow us!

Send this to a friend